* patient already prescribed chloroquine or hydroxychloroquine * allergy to hydroxychloroquine * history of bone marrow or solid organ transplant * known g6pd deficiency * chronic hemodialysis, peritoneal dialysis, continuous renal replacement therapy or glomerular filtration rate \< 20ml/min/1.73m2 * known liver disease (e.g. child pugh score ≥ b or ast\>2 times upper limit) * psoriasis * porphyria * known cardiac conduction delay (qtc \> 500msec) or taking any prescription medications known to prolong qt interval * concomitant use of digitalis, flecainide, amiodarone, procainamide, or propafenone * seizure disorder * prisoner * weight \< 35kg * inability to follow-up - no cell phone or no address or not spanish or english speaking * receipt of any experimental treatment for sars-cov-2 (off-label, compassionate use, or trial related) within the 30 days prior to the time of the screening evaluation * patient or another member of patient's household has been already enrolled in this study.

* patient already prescribed chloroquine or hydroxychloroquine * allergy to hydroxychloroquine * history of bone marrow or solid organ transplant * known g6pd deficiency * chronic hemodialysis, peritoneal dialysis, continuous renal replacement therapy or glomerular filtration rate \< 20ml/min/1.73m2 * known liver disease (e.g. child pugh score ≥ b or ast\>2 times upper limit) * psoriasis * porphyria * known cardiac conduction delay (qtc \> 500msec) or taking any prescription medications known to prolong qt interval * concomitant use of digitalis, flecainide, amiodarone, procainamide, or propafenone * seizure disorder * prisoner * weight \< 35kg * inability to follow-up - no cell phone or no address or not spanish or english speaking * receipt of any experimental treatment for sars-cov-2 (off-label, compassionate use, or trial related) within the 30 days prior to the time of the screening evaluation * patient or another member of patient's household has been already enrolled in this study.

- patient already prescribed chloroquine or hydroxychloroquine - allergy to hydroxychloroquine - history of bone marrow or solid organ transplant - known g6pd deficiency - chronic hemodialysis, peritoneal dialysis, continuous renal replacement therapy or glomerular filtration rate < 20ml/min/1.73m2 - known liver disease (e.g. child pugh score ≥ b or ast>2 times upper limit) - psoriasis - porphyria - known cardiac conduction delay (qtc > 500msec) or taking any prescription medications known to prolong qt interval - concomitant use of digitalis, flecainide, amiodarone, procainamide, or propafenone - seizure disorder - prisoner - weight < 35kg - inability to follow-up - no cell phone or no address or not spanish or english speaking - receipt of any experimental treatment for sars-cov-2 (off-label, compassionate use, or trial related) within the 30 days prior to the time of the screening evaluation - patient or another member of patient's household has been already enrolled in this study.

- patient already prescribed chloroquine or hydroxychloroquine - allergy to hydroxychloroquine - history of bone marrow or solid organ transplant - known g6pd deficiency - chronic hemodialysis, peritoneal dialysis, continuous renal replacement therapy or glomerular filtration rate < 20ml/min/1.73m2 - known liver disease (e.g. child pugh score ≥ b or ast>2 times upper limit) - psoriasis - porphyria - known cardiac conduction delay (qtc > 500msec) or taking any prescription medications known to prolong qt interval - concomitant use of digitalis, flecainide, amiodarone, procainamide, or propafenone - seizure disorder - prisoner - weight < 35kg - inability to follow-up - no cell phone or no address or not spanish or english speaking - receipt of any experimental treatment for sars-cov-2 (off-label, compassionate use, or trial related) within the 30 days prior to the time of the screening evaluation - patient or another member of patient's household has been already enrolled in this study.